STOCK TITAN

Pacira BioSciences Inc - PCRX STOCK NEWS

Welcome to our dedicated news page for Pacira BioSciences (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacira BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacira BioSciences's position in the market.

Rhea-AI Summary
Pacira BioSciences, Inc. receives RMAT designation from FDA for PCRX-201 gene therapy product candidate for osteoarthritis. Positive Phase 1 study results show efficacy for at least 52 weeks. Additional data to be presented at OARSI 2024. RMAT designation expedites development process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference. The event will take place on March 13, 2024, in Miami, at 1:35 PM ET. Live audio can be accessed on the company's website. A replay will be available for two weeks post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) reported record revenues of $675 million in 2023, with full-year GAAP net income of $42 million and adjusted EBITDA of $214 million. EXPAREL surpassed the 14 million patient mark, and the FDA approved new manufacturing suite and label expansions. The company appointed Frank D. Lee as CEO, aiming for long-term growth and operational excellence in pain management solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
earnings
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) will release its Q4 and full-year 2023 financial results on February 29, 2024. A live conference call and webcast will follow, allowing participants to engage in a Q&A session. The event will be accessible via webcast and replay options for those unable to join live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences earnings
-
Rhea-AI Summary
Pacira BioSciences, Inc. announced positive results from a Phase 3 study on EXPAREL for sciatic nerve block in bunionectomy patients. The study showed significant pain reduction and opioid consumption over 96 hours compared to bupivacaine HCl, with EXPAREL leading to 61% fewer opioids used and 24.4% of patients not needing rescue opioids. The safety profiles of EXPAREL and bupivacaine HCl were similar, with mild to moderate adverse events. EXPAREL offers a non-opioid pain management solution for foot and ankle procedures, enhancing outpatient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) has secured a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc., effective January 1, 2024. This agreement allows Premier members to access special pricing for EXPAREL® (bupivacaine liposome injectable suspension), a single-dose local and regional analgesic, aimed at improving patient care and reducing reliance on opioids. The collaboration is expected to expand Pacira's reach and provide non-opioid pain management options to more patients. Premier, with its extensive network of U.S. hospitals and health systems, aims to transform healthcare by enabling better care and outcomes at a lower cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
none
Rhea-AI Summary
Paradise PB Events and G.O.A.T. Paddle announced the expansion of G.O.A.T. Bowl I tournament play in Las Vegas to 24 teams and the signing of new sponsors. The tournament is set for Feb. 9 and will feature a full day of pickleball festivities, including amateur competition, food truck line-up, tailgate party, skills challenge, and festival atmosphere. The expansion is due to high demand for participation from the pickleball community. The tournament is produced by Paradise PB Events and presented by Pacira BioSciences' ZILRETTA®. Oso Pickleball has been named the official ball sponsor, and Dunkin' has been added to the line-up of event supporters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023, compared with $666.8 million for the year ended December 31, 2022. The company's fourth quarter EXPAREL net product sales were $143.9 million in 2023, with a 4% average daily volume growth. Full-year EXPAREL net product sales were $538.1 million in 2023, with a 5% average daily volume growth. The company also announced plans for long-term growth initiatives and the upcoming launch of EXPAREL in two key lower extremity nerve blocks in 2024, as well as the expansion of patient access with the rollout of the NOPAIN Act in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
Rhea-AI Summary
Pacira BioSciences, Inc. (Nasdaq: PCRX) appoints Frank D. Lee as CEO and member of the Board, effective January 2, 2024. Paul J. Hastings named Chair of the Board. David Stack to remain in advisory role through August 2025. Lee brings more than three decades of global experience in pharmaceutical and biotechnology product development and commercialization. He has a strong track record of leadership success and has held executive positions at Forma Therapeutics, Genentech, Novartis, Janssen, and Eli Lilly. Lee's appointment comes with inducement awards, including a non-qualified stock option and a restricted stock unit award.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
management
Pacira BioSciences Inc

Nasdaq:PCRX

PCRX Rankings

PCRX Stock Data

1.36B
46.02M
1.24%
107.78%
8.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Parsippany

About PCRX

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.